Cargando…
Lupoid cutaneous leishmaniasis in Afghanistan treated with 0.045% DAC N-055
Autores principales: | Stahl, KW, Sakhayeee, IG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239674/ http://dx.doi.org/10.1186/1753-6561-5-S6-P247 |
Ejemplares similares
-
0.045% DAC N-055 a choice for poor Afghan surgical patients?
por: Stahl, KW, et al.
Publicado: (2011) -
A randomized controlled phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electro-cauterization versus intralesional antimony in Afghanistan
por: Stahl, Hans-Christian, et al.
Publicado: (2014) -
Salvage therapy with Sodium chlorosum (formerly DAC N-055) for cases of refractory lupoid cutaneous leishmaniasis: results from a compassionate use study with 0.09% Sodium chlorosum in amphiphilic basic cream
por: Molkara, Sara, et al.
Publicado: (2019) -
Lupoid cutaneous leishmaniasis: a case report
por: Khaled, Aida, et al.
Publicado: (2011) -
Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
por: Reddy, Vidhatha, et al.
Publicado: (2020)